Momelotinib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 100 mg, 150 mg, 200 mg
Reference Brands: Ojjaara (USA)
Category: Oncology Cancer Care
Momelotinib is available in Tablets and strengths such as 100 mg, 150 mg, 200 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Momelotinib is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Momelotinib can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Momelotinib is an oral anticancer medication used for the treatment of myelofibrosis, a rare bone marrow disorder characterized by abnormal blood cell production, splenomegaly, and anemia. It is marketed under the brand name Ojjaara and belongs to the class of Janus kinase (JAK) inhibitors. Momelotinib works by inhibiting JAK1 and JAK2 signaling pathways involved in inflammation and abnormal cell proliferation, while also modulating pathways related to anemia, making it a differentiated therapy for patients with myelofibrosis.
Momelotinib is indicated for adult patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis and secondary myelofibrosis arising from polycythemia vera or essential thrombocythemia. The medication is administered orally, offering convenience for long-term disease management.
Common adverse reactions associated with momelotinib therapy include dizziness, fatigue, diarrhea, nausea, thrombocytopenia, hemorrhage, and bacterial infections. Due to these potential effects, patients receiving momelotinib require regular clinical and laboratory monitoring. Overall, momelotinib provides an important targeted treatment option for managing myelofibrosis, particularly in patients with disease-related anemia, supporting improved symptom control and quality of life.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Momelotinib is used for the treatment of adult patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis and secondary myelofibrosis following polycythemia vera or essential thrombocythemia. It is particularly beneficial for patients with anemia associated with myelofibrosis.
Momelotinib is a small-molecule kinase inhibitor that targets Janus kinase (JAK) 1 and 2 and activin A receptor type 1 (ACVR1), helping regulate inflammatory signaling and hepcidin production.
The trade name of momelotinib is Ojjaara.
Momelotinib is developed and marketed by GSK (GlaxoSmithKline).
The generic name is momelotinib.
The brand name is Ojjaara.
Momelotinib is manufactured in GMP-compliant pharmaceutical facilities for commercial supply in the United States.
Related Products
Nirogacestat
Strength:
50 mg
Form: Tablets
Reference Brands: Generic formulations marketed under different names
View Details
Nintedanib
Strength:
100 mg, 150 mg
Form: Capsules
Reference Brands: Ofev (USA, EU), Vargatef (EU)
View Details
Quick Response Guaranteed | Verified Suppliers
